Several studies on conventional drugs and new treatments in inflammatory bowel 
disease were presented in Digestive Disease Week 2013. Various studies have 
compared infliximab and cyclosporin in corticosteroid-refractory ulcerative 
colitis in clinical practice, providing complementary information to the CYSIF 
clinical trial. For the first time, a clinical trial has evaluated the efficacy 
of adalimumab in preventing recurrence of Crohn's disease after surgery. The 
results of some studies suggest that thiopurines improve response to infliximab, 
in both Crohn disease and ulcerative colitis. Finally, several studies were 
presented on new drugs with new therapeutic targets, such as vedolizumab, in the 
treatment of inflammatory bowel disease. The preliminary results of the ASTIC 
trial were reported, which evaluated the safety and efficacy of bone marrow 
transplantation in Crohn's disease.